Posts by: Margarida Azevedo, MSc

Margarida Azevedo, MSc

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

February 6, 2017

RondinX’s New Microbiome Platform a Potential Tool for IBD Drug Discovery

News

RondinX has developed a breakthrough platform that profiles and predicts gut microbial growth dynamics by using genetic material of human gut samples. The technology may be key to understanding the ... Read more

February 3, 2017February 3, 2017

Cognitive Behavioral Therapy Seen as Best at Helping IBD Patients Improve Quality of Life

News

Psychological therapy, especially cognitive behavioral therapy, can help to ease depression and improve quality of life in patients with inflammatory bowel disease (IBD), but generally only for the short term, a ... Read more

February 2, 2017

InDex and Parexel to Collaborate in Phase 2b CONDUCT Study of Kappaproct for UC

News

InDex Pharmaceuticals and the contract research organization (CRO) Parexel are partnering to manage the overseas Phase 2b CONDUCT dose optimization clinical trial of Kappaproct (cobitolimod) for the treatment of moderate to severe active ... Read more

February 1, 2017February 1, 2017

Refusing to Allow Crohn’s Disease to Hijack My Freedom to Travel

Columns, Crohn's Corner - a column by Judy Walters

Now that my children are grown (mostly) and out of the house, one at college, one at graduate school, I have vowed to travel a bit more. Besides financial constraints ... Read more

January 31, 2017January 31, 2017

Relapse Common in IBD Patients Who Stop Anti-TNF Therapy, But Can Take Years, Study Finds

News

Nearly half of the more than 1,000 people with inflammatory bowel disease (IBD) in clinical remission had a relapse some three years after stopping anti-tumor necrosis factor (anti-TNF) treatment — and more than half relapsed ... Read more

January 30, 2017January 30, 2017

EU Approval of Humira Biosimilar, ABP501, to Treat Adults and Children with IBD Favored

News

ABP501, a biosimilar of Humira (adalimumab), was recommended for approval in the European Union to treat adults and some children with various inflammatory diseases, including inflammatory bowel disease (IBD), by the Committee for Medicinal ... Read more

January 27, 2017January 27, 2017

Vaccinations and Other Preventive Care Measures Stressed in New IBD Guideline

News

The importance of preventive care to people with inflammatory bowel disease (IBD) is stressed in a new guideline by the American College of Gastroenterology (ACG), with specific recommendations of measures IBD ... Read more

January 26, 2017January 26, 2017

Crohn’s and the Prednisone Taper: Love/Hate Relationship Continues

Columns, Crohn's Corner - a column by Judy Walters

If you’ve ever been on Prednisone, you know it is a love/hate kind of thing. I love it when I’m feeling so awful that I can’t get out of bed, ... Read more

January 25, 2017

Crohn’s and Colitis Patients Sought for Study to Increase Knowledge of Disease

News

A new study aimed at better understanding Crohn’s disease and ulcerative colitis is recruiting patients in Scotland and England with either of the debilitating bowel conditions. The PREdiCCt study, led ... Read more

January 23, 2017

European Consortium Awarded Millions to Develop Therapies for IBD, 2 Other Inflammatory Diseases

News

A new European project coordinated by Kiel University in Germany has been awarded with €14.4 million euros (about $15.3 million U.S. dollars) to develop a personalized medicine approach for predicting ... Read more